Schedule 13G ownership disclosure

Janux Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 47103J105

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Paradigm BioCapital Advisors LP

    Shares: 2,920,258.00 · Class: 4.9%

  • Paradigm BioCapital Advisors GP LLC

    Shares: 2,920,258.00 · Class: 4.9%

  • Senai Asefaw, M.D.

    Shares: 2,920,258.00 · Class: 4.9%

  • Paradigm BioCapital International Fund Ltd.

    Shares: 2,593,376.00 · Class: 4.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-078664
Form type
SCHEDULE 13G/A
Filer
Janux Therapeutics, Inc.
CIK
CIK 1817713
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub